Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature

United States Drug Enforcement Administration. Drug scheduling. Accessed January 31, 2020. https://www.dea.gov/drug-scheduling

National Conference of State Legislatures. State Medical Marijuana Laws. Updated October 16, 2019. Accessed January 29, 2019. https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx

Ebbert JO Scharf EL Hurt RT. Medical cannabis. Mayo Clin Proc. 2018;93:1842-1847. doi:10.1016/j.mayocp.2018.09.005

Leafly Holdings, Inc. Qualifying conditions for medical marijuana by state. Accessed December 19, 2019. https://www.leafly.com/news/health/qualifying-conditions-for-medical-marijuana-by-state

National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research. National Academies Press; 2017. Accessed March 17, 2019. http://nationalacademies.org/hmd/reports/2017/health-effects-of-cannabis-and-cannabinoids.aspx

Clinical Pharmacology powered by ClinicalKey [database online]. Updated 2019. Accessed March 25, 2019. http://www.clinicalpharmacology.com

Lexicomp Online [database online]. Updated March 2019. Accessed March 25, 2019. https://online.lexi.com

Micromedex Healthcare Series [database online]. Updated 2019. Accessed March 25, 2019. http://www.micromedexsolutions.com/micromedex2/librarian

Marinol [package insert]. Chicago, IL: AbbVie Inc; 2017.

Syndros® [package insert]. Lakewood, NJ: Insys Therapeutics, Inc; 2018.

Cesamet® [package insert]. Somerset, NJ: Meda Pharmaceuticals, Inc; 2020.

Epidiolex® [package insert]. Carlsbad, CA: Greenwich Biosciences, Inc; 2018.

GW Pharmaceuticals. Information on obtaining Sativex®. Accessed March 7, 2019. https://www.gwpharm.com/healthcare-professionals/sativex/prescribing-information

Utah Medical Cannabis Act of 2018, HB 3001, 2018 Leg, 3rd Special Sess (Ut 2019).

Whiting PF Wolff RF Deshpande S , et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456-2473. doi:10.1001/jama.2015.6358

Shelef A Barak Y Berger U , et al. Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study. J Alzheimers Dis. 2016;51:15-19. doi:10.3233/JAD-150915

Ruthirakuhan M Lanctôt KL Vieira D Herrmann N. Natural and synthetic cannabinoids for agitation and aggression in Alzheimer’s disease: a meta-analysis. J Clin Psychiatry. 2019;80:18r12617. doi:10.4088/JCP.18r12617

van den Elsen GA Tobben L Ahmed AI , et al. Effects of tetrahydrocannabinol on balance and gait in patients with dementia: a randomized controlled crossover trial. J Psychopharmacol. 2017;31:184-191. doi:10.1177/0269881116665357

van den Elsen GA Ahmed AI Verkes RJ , et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology. 2015;84:2338-2346. doi:10.1212/WNL.0000000000001675

van den Elsen GA Ahmed AI Verkes RJ Feuth T van der Marck MA Olde Rikkert MGM. Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial. Am J Geriatr Psychiatry. 2015;23:1214-1224. doi:10.1016/j.jagp.2015.07.011

Ahmed A Elsen G Colbers A , et al. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology. 2015;232:2587-2595. doi:10.1007/s00213-015-3889-y

Woodward MR Harper DG Stolyar A Forester BP Ellison JM. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry. 2014;22:415-419. doi:10.1016/j.jagp.2012.11.022

Walther S Schüpbach B Seifritz E Homan P Strik W. Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol. 2011;31:256-258. doi:10.1097/JCP.0b013e31820e861c

Walther S Mahlberg R Eichmann U Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl). 2006;185:524-528. doi:10.1007/s00213-006-0343-1

Volicer L Stelly M Morris J McLaughlin J Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 1997;12:913-919.

Passmore MJ. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int J Geriatr Psychiatry. 2008;23:116-117. doi:10.1002/gps.1828

Amanullah S MacDougall K Sweeney N Coffin J Cole J. Synthetic cannabinoids in dementia with agitation: case studies and literature review. Clin Neuropsychiatry. 2013;10:142-147.

Rabins PV Blacker D Rovner BW , et al. Treatment of Patients With Alzheimer’s Disease and Other Dementias. 2nd ed. American Psychiatric Association; 2007.

Rabins PV Rovner BW Rummans T Schneider LS Tariot PN. Guideline Watch (October 2014): practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Accessed May 6, 2019. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/alzheimerwatch.pdf

Hort J O’Brien JT Gainotti G , et al; EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010;17:1236-1248. doi:10.1111/j.1468-1331.2010.03040.x

Sorbi S Hort J Erkinjuntti T , et al; EFNS Scientist Panel on Dementia and Cognitive Neurology. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19:1159-1179. doi:10.1111/j.1468-1331.2012.03784.x

O’Brien JT Holmes C Jones M , et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017;31:147-168. doi:10.1177/0269881116680924

Ihl R Frölich L Winbland B Schneider L Burns A Möller HJ ; WFSBP Task Force on Treatment Guidelines for Alzheimer’s Disease and other Dementias. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer’s disease and other dementias. World J Biol Psychiatry. 2011;12:2-32. doi:10.3109/15622975.2010.538083

Weber M Goldman B Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg Psychiatry. 2010;81:1135-1140. doi:10.1136/jnnp.2009.200642

Chiò A Mora G Lauria G. Pain in amyotrophic lateral sclerosis. Lancet Neurol. 2017;16:144-157. doi:10.1016/S1474-4422(16)30358-1

Gelinas D Miller RG Abood ME. A pilot study of safety and tolerability of delta 9-THC (Marinol) treatment for ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(suppl 1):23-24.

Riva N Mora G Sorarù G , et al. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18:155-164. doi:10.3109/17482968.2012.687264

Joerger M Wilkins J Fagagnini S , et al. Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis. Drug Metab Lett. 2012;6:102-108. doi:10.2174/1872312811206020102

EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis; Andersen PM Abrahams S , et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS Task Force. Eur J Neurol. 2012;19:360-375. doi:10.1111/j.1468-1331.2011.03501.x

Miller RG Jackson CE Kasarskis EJ , et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1218-1226. doi:10.1212/WNL.0b013e3181bc0141

Andersen PM Borasio GD Dengler R , et al; EALSC Working Group. Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler. 2007;8:195-213. doi:10.1080/17482960701262376

Barchel D Stolar O De-Haan T , et al. Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol. 2019;9:1521. doi:10.3389/fphar.2018.01521

Schleider LBL Mechoulam R Saban N Meiri G Novack V . Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep. 2019;9:200. doi:10.1038/s41598-018-37570-y

Aran A Cassuto H Lubotzky A Wattad N Hazan E. Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems—a retrospective feasibility study. J Autism Dev Disord. 2019;49:1284-1288. doi:10.1007/s10803-018-3808-2

Kuester G Vergara K Ahumada A Gazmuri AM. Oral cannabis extracts as a promising treatment for the core symptoms of autism spectrum disorder: preliminary experience in Chilean patients. J Neurol Sci. 2017;381:932-933. doi:10.1016/j.jns.2017.08.2623

Poleg S Golubchik P Offen D Weizman A. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2019;89:90-96. doi:10.1016/j.pnpbp.2018.08.030

Salgado CA Castellanos D. Autism spectrum disorder and cannabidiol: have we seen this movie before? Glob Pediatr Health. 2018;5:2333794X18815412. doi:10.1177/2333794X18815412

Cooper RE Williams E Seegobin S Tye C Kuntsi J Asherson P. Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27:795-808. doi:10.1016/j.euroneuro.2017.05.005

Kurz R Blass K. Use of dronabinol (delta-9-THC) in autism: a prospective single-case-study with an early infantile autistic child. Cannabinoids. 2010;5:4-6.

Aran A. Cannabinoids for behavioral problems in children with ASD. ClinicalTrials.gov identifier: NCT02956226. Published November 6, 2016. Accessed April 10, 2019. https://www.clinicaltrials.gov/ct2/show/NCT02956226

Cannabidiol for ASD open trial. ClinicalTrials.gov identifier: NCT03900923. Published April 3, 2019. Accessed April 10, 2019. https://clinicaltrials.gov/ct2/show/NCT03900923

Cannabidivarin (CBDV) vs placebo in children with autism spectrum disorder (ASD). ClinicalTrials.gov identifier: NCT03202303. Published June 28, 2017. Accessed April 10, 2019. https://clinicaltrials.gov/ct2/show/NCT03202303

Safety and tolerability of cannabidivarin (CBDV) in children and young adults with autism spectrum disorder. ClinicalTrials.gov identifier: NCT03849456. Published February 21, 2019. Accessed April 10, 2019. https://clinicaltrials.gov/ct2/show/NCT03849456

Howes OD Rogdaki M Findon JL , et al. Autism spectrum disorder: CONSENSUS guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol. 2018;32:3-29. doi:10.1177/0269881117741766

Committee on Substance Abuse, Committee on Adolescence; Committee on Substance Abuse Committee on Adolescence. The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics. 2015;135:584-587. doi:10.1542/peds.2014-4146

Jatoi A Windschitl HE Loprinzi CL , et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20:567-573.

Brisbois TD de Kock IH Watanabe SM , et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011;22:2086-2093. doi:10.1093/annonc/mdq727

Nelson K Walsh D Deeter P Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care. 1994;10:14-18.

Plasse TF Gorter RW Krasnow SH Lane M Shepard KV Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav. 1991;40:695-700.

Cannabis-In-Cachexia-Study-Group; Strasser F Luftner D , et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006;24:3394-3400.

Turcott JG Del Rocío Guillen Núñez M Flores-Estrada D , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer. 2018;26:3029-3038. doi:10.1007/s00520-018-4154-9

Anderson SP Zylla DM McGriff DM Arneson TJ. Impact of medical cannabis on patient-reported symptoms for patients with cancer enrolled in Minnesota’s medical cannabis program. J Oncol Pract. 2019;15:e338-e345. doi:10.1200/JOP.18.00562

Guzman M Duarte MJ Blazquez C , et al. A pilot clinical study of delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95:197-203.

Foroughi M Hendson G Sargent MA Steinbok P. Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas—possible role of cannabis inhalation. Childs Nerv Syst. 2011;27:671-679. doi:10.1007/s00381-011-1410-4

Singh Y Bali C. Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation. Case Rep Oncol. 2013;6:585-592. doi:10.1159/000356446

Häuser W Welsch P Klose P Radbruch L Fitzcharles MA. Efficacy, tolerability and safety of cannabis-based medicines for cancer pain: a systematic review with meta-analysis of randomised controlled trials. Schmerz. 2019;33:424-436. doi:10.1007/s00482-019-0373-3

Mücke M Weier M Carter C , et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle. 2018;9:220-234. doi:10.1002/jcsm.12273

Lichtman AH Lux EA McQuade R , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage. 2018;55:179-188.e1. doi:10.1016/j.jpainsymman.2017.09.001

Fallon MT Lux EA McQuade R , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain. 2017;11:119-133. doi:10.1177/2049463717710042

Portenoy RK Ganae-Motan ED Allende S , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13:438-449. doi:10.1016/j.jpain.2012.01.003

Johnson JR Burnell-Nugent M Lossignol D Ganae-Motan ED Potts R Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39:167-179.

Johnson JR Lossignol D Burnell-Nugent M Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013;46:207-218. doi:10.1016/j.jpainsymman.2012.07.014

Lynch ME Cesar-Rittenberg P Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. 2014;47:166-173. doi:10.1016/j.jpainsymman.2013.02.018

Maida V Ennis M Irani S Corbo M Dolzhykov M. Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J Support Oncol. 2008;6:119-124.

Bar-Sela G Vorobeichik M Drawsheh S Omer A Goldberg V Muller E. The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients on supportive or palliative care. Evid Based Complement Alternat Med. 2013;2013:510392. doi:10.1155/2013/510392

Dans M Smith T Back A , et al. NCCN guidelines insights: palliative care, version 2.2017. J Natl Compr Canc Netw. 2017;15:989-997. doi:10.6004/jnccn.2017.0132

Lattanzi S Brigo F Trinka E , et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs. 2018;78:1791-1804. doi:10.1007/s40265-018-0992-5

Devinsky O Patel AD Cross JH , et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888-1897. doi:10.1056/NEJMoa1714631

Thiele EA Marsh ED French JA , et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085-1096. doi:10.1016/S0140-6736(18)30136-3

Devinsky O Patel AD Thiele EA , et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204-e1211. doi:10.1212/WNL.0000000000005254

Devinsky O Cross JH Laux L , et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011-2020. doi:10.1056/NEJMoa1611618

Devinsky O Verducci C Thiele EA , et al. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131-137. doi:10.1016/j.yebeh.2018.05.013

Chen KA Farrar M Cardamone M , et al. Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience. Med J Aust. 2018;209:217-221.

Szaflarski JP Bebin EM Comi AM , et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia. 2018;59:1540-1548. doi:10.1111/epi.14477

Devinsky O Marsh E Friedman D , et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270-278. Published correction appears in Lancet Neurol. 2016;15:352. doi:10.1016/S1474-4422(15)00379-8

Hess EJ Moody KA Geffrey AL , et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57:1617-1624. doi:10.1111/epi.13499

Rosenberg EC Tsien RW Whalley BJ Devinsky O. Cannabinoids and epilepsy. Neurotherapeutics. 2015;12:747-768. doi:10.1007/s13311-015-0375-5

Geffrey AL Pollack SF Bruno PL Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56:1246-1251. doi:10.1111/epi.13060

Hausman-Kedem M Menascu S Kramer U. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents—an observational, longitudinal study. Brain Dev. 2018;40:544-551. doi:10.1016/j.braindev.2018.03.013

Porcari GS Fu C Doll ED Carter EG Carson RP. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: practical experiences in a tertiary medical center. Epilepsy Behav. 2018;80:240-246. doi:10.1016/j.yebeh.2018.01.026

Suraev AS Todd L Bowen MT , et al. An Australian nationwide survey on medicinal cannabis use for epilepsy: history of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy Behav. 2017;70(pt B):334-340. doi:10.1016/j.yebeh.2017.02.005

Treat L Chapman KE Colborn KL Knupp KG. Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. Epilepsia. 2017;58:123-127. doi:10.1111/epi.13617

Sulak D Saneto R Goldstein B. The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy Behav. 2017;70(pt B):328-333. doi:10.1016/j.yebeh.2016.12.032

Aguirre-Velázquez CG. Report from a survey of parents regarding the use of cannabidiol (medicinal cannabis) in Mexican children with refractory epilepsy. Neurol Res Int. 2017;2017:2985729. doi:10.1155/2017/2985729

Tzadok M Uliel-Siboni S Linder I , et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure. 2016;35:41-44. doi:10.1016/j.seizure.2016.01.004

Hussain SA Zhou R Jacobson C , et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015;47:138-141. doi:10.1016/j.yebeh.2015.04.009

Press CA Knupp KG Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49-52. doi:10.1016/j.yebeh.2015.02.043

Porter BE Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29:574-577. doi:10.1016/j.yebeh.2013.08.037

Crippa JA Crippa AC Hallak JE Martín-Santos R Zuardi AW. Δ9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. Front Pharmacol. 2016;7:359. doi:10.3389/fphar.2016.00359

National Institute for Health and Care Excellence. Epilepsies: diagnosis and management clinical guideline. Clinical guideline: CG137. Published January 11, 2012. Updated April 2018. Accessed April 1, 2019. https://www.nice.org.uk/guidance/cg137

Koppel BS Brust JC Fife T , et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556-1563. doi:10.1212/WNL.0000000000000363

Kanner AM Ashman E Gloss D , et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91:82-90. Published correction appears in Neurology. 2018;91:1117. doi:10.1212/WNL.0000000000005756

American Epilepsy Society. AES Position Statement on cannabis as a treatment for patients with epileptic seizures. Updated February 19, 2019. Accessed April 1, 2019. https://www.aesnet.org/about_aes/position_statements/AES%20Position%20on%20Medical%20Marijuana

Belendiuk KA Baldini LL Bonn-Miller MO. Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract. 2015;10:10. doi:10.1186/s13722-015-0032-7

Bowen LL McRae-Clark AL. Therapeutic benefit of smoked cannabis in randomized placebo-controlled studies. Pharmacotherapy. 2018;38:80-85. doi:10.1002/phar.2064

Lutge EE Gray A Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev. 2013;(4):CD005175. doi:10.1002/14651858.CD005175.pub3

Woolridge E Barton S Samuel J Osorio J Dougherty A Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage. 2005;29:358-367. doi:10.1016/j.jpainsymman.2004.07.011

Abrams DI Jay CA Shade SB , et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68:515-521. doi:10.1212/01.wnl.0000253187.66183.9c

Andreae MH Carter GM Shaparin N , et al. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. J Pain. 2015;16:1221-1232. doi:10.1016/j.jpain.2015.07.009

Ellis RJ Toperoff W Vaida F , et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34:672-680. doi:10.1038/npp.2008.120

Phillips TJ Cherry CL Cox S Marshall SJ Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2010;5:e14433. doi:10.1371/journal.pone.0014433

Haney M. Effects of smoked marijuana in healthy and HIV + marijuana smokers. J Clin Pharmacol. 2002;42(S1):34S-40S. doi:10.1002/j.1552-4604.2002.tb06001.x

Haney M Rabkin J Gunderson E Foltin RW. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl). 2005;181:170-178. doi:10.1007/s00213-005-2242-2

Haney M Gunderson EW Rabkin J , et al. Dronabinol and marijuana in HIV-positive marijuana smokers: caloric intake, mood, and sleep. J Acquir Immune Defic Syndr. 2007;45:545-554. doi:10.1097/QAI.0b013e31811ed205

Riggs PK Vaida F Rossi SS , et al. A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res. 2012;1431:46-52. doi:10.1016/j.brainres.2011.11.001

Okafor CN Zhou Z Burrell LE II , et al. Marijuana use and viral suppression in persons receiving medical care for HIV-infection. Am J Drug Alcohol Abuse. 2017;43:103-110. doi:10.1080/00952990.2016.1191505

Abrams DI Hilton JF Leiser RJ , et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2003;139:258-266. doi:10.7326/0003-4819-139-4-200308190-00008

Jiang W Luo Z Martin L , et al. Drug use is associated with anti-CD4 IgG-mediated CD4+ T cell death and poor CD4+ T cell recovery in viral-suppressive HIV-infected individuals under antiretroviral therapy. Curr HIV Res. 2018;16:143-150. doi:10.2174/1570162X16666180703151208

Milloy MJ Marshall B Kerr T , et al. High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load among recently infected people who use injection drugs. Drug Alcohol Rev. 2015;34:135-140. doi:10.1111/dar.12223

Thames AD Mahmood Z Burggren AC Karimian A Kuhn TP. Combined effects of HIV and marijuana use on neurocognitive functioning and immune status. AIDS Care. 2016;28:628-632. doi:10.1080/09540121.2015.1124983

Thompson AB Gillespie SE Hood J Thomas-Seaton L Hussen SA Camacho-Gonzalez AF. Regular marijuana use is associated with poor viral suppression in HIV-infected adolescents and young adults. AIDS Behav. 2018;22:1363-1372. doi:10.1007/s10461-017-1961-9

Sinha S McCaul ME Hutton HE , et al. Marijuana use and HIV treatment outcomes among PWH receiving care at an urban HIV clinic. J Subst Abuse Treat. 2017;82:102-106. doi:10.1016/j.jsat.2017.09.009

Costantino CM Gupta A Yewdall AW Dale BM Devi LA Chen BK. Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells. PLoS One. 2012;7:e33961. doi:10.1371/journal.pone.0033961

Bonn-Miller MO Oser ML Bucossi MM Trafton JA. Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. J Behav Med. 2014;37:1-10. doi:10.1007/s10865-012-9458-5

Lake S Kerr T Capler R Shoveller J Montaner J Milloy MJ. High-intensity cannabis use and HIV clinical outcomes among HIV-positive people who use illicit drugs in Vancouver, Canada. Int J Drug Policy. 2017;42:63-70. doi:10.1016/j.drugpo.2017.02.009

Vidot DC Lerner B Gonzalez R. Cannabis use, medication management and adherence among persons living with HIV. AIDS Behav. 2017;21:2005-2013. doi:10.1007/s10461-017-1782-x

Sohler NL Starrels JL Khalid L , et al. Cannabis use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain. Subst Use Misuse. 2018;53:1602-1607. doi:10.1080/10826084.2017.1416408

Goldenberg M Reid MW IsHak WW Danovitch I. The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: a systematic review and meta-analysis. Drug Alcohol Depend. 2017;174:80-90. doi:10.1016/j.drugalcdep.2016.12.030

Korthuis PT Zephyrin LC Fleishman JA , et al; HIV Research Network. Health-related quality of life in HIV-infected patients: the role of substance use. AIDS Patient Care STDS. 2008;22:859-867. doi:10.1089/apc.2008.0005

Sherbourne CD Hays RD Fleishman JA , et al. Impact of psychiatric conditions on health-related quality of life in persons with HIV infection. Am J Psychiatry. 2000;157:248-254. doi:10.1176/appi.ajp.157.2.248

Brunet L Moodie EE Rollet K , et al. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. Clin Infect Dis. 2013;57:663-670. doi:10.1093/cid/cit378

Farooqui MT Khan MA Cholankeril G , et al. Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019;31:149-156. doi:10.1097/MEG.0000000000001263

Kelly EM Dodge JL Sarkar M , et al. Marijuana use is not associated with progression to advanced liver fibrosis in HIV/hepatitis C virus–coinfected women. Clin Infect Dis. 2016;63:512-518. doi:10.1093/cid/ciw350

Nordmann S Vilotitch A Roux P , et al. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus–co-infected patients (ANRS CO13-HEPAVIH). J Viral Hepat. 2018;25:171-179. doi:10.1111/jvh.12797

Lorenz DR Uno H Wolinsky SM Gabuzda D. Effect of marijuana smoking on pulmonary disease in HIV-infected and uninfected men: a longitudinal cohort study. EClinicalMedicine. 2019;7:55-64. doi:10.1016/j.eclinm.2019.01.003

Skalski LM Towe SL Sikkema KJ Meade CS. The impact of marijuana use on memory in HIV-infected patients: a comprehensive review of the HIV and marijuana literatures. Curr Drug Abuse Rev. 2016;9:126-141. doi:10.2174/1874473709666160502124503

Cristiani SA Pukay-Martin ND Bornstein RA. Marijuana use and cognitive function in HIV-infected people. J Neuropsychiatry Clin Neurosci. 2004;16:330-335. doi:10.1176/jnp.16.3.330

US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Accessed April 29, 2019. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0

World Health Organization. Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations—2016 Update. World Health Organization; 2016.

Kafil TS Nguyen TM MacDonald JK Chande N. Cannabis for the treatment of Crohn’s disease. Cochrane Database Syst Rev. 2018;(11):CD012853. doi:10.1002/14651858.CD012853.pub2

Kafil TS Nguyen TM MacDonald JK Chande N. Cannabis for the treatment of ulcerative colitis. Cochrane Database Syst Rev. 2018;(11):CD012954. doi:10.1002/14651858.CD012954.pub2

Naftali T Schleider LBL Dotan I Lansky EP Benjaminov FS Konikoff FM. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11:1276-1280.e1. doi:10.1016/j.cgh.2013.04.034

Naftali T Barlev L Gabay G , et al. P358 tetrahydrocannabinol (THC) induces clinical and biochemical improvement with a steroid sparing effect in active inflammatory bowel disease. J Crohns Colitis. 2013;7(suppl 1):S153. doi:10.1016/S1873-9946(13)60379-7

Lahat A Lang A Ben-Horin S. Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion. 2012;85:1-8. doi:10.1159/000332079

Naftali T Lev LB Yablecovitch D Half E Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J. 2011;13:455-458.

Irving PM Iqbal T Nwokolo C , et al. A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis. 2018;24:714-724. doi:10.1093/ibd/izy002

Naftali T Mechulam R Marii A , et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn’s disease, a randomized controlled trial. Dig Dis Sci. 2017;62:1615-1620. doi:10.1007/s10620-017-4540-z

Naftali T Mechoulam R Gabay GG , et al. 983: Cannabidiol treatment does not effect active Crohn’s disease. Gastroenterology. 2013;144(5, suppl 1):S-180. doi:10.1016/S0016-5085(13)60641-1

Rubin DT Ananthakrishnan AN Siegel CA Sauer BG Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384-413. doi:10.14309/ajg.0000000000000152

Ko CW Singh S Feuerstein JD , et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156:748-764. doi:10.1053/j.gastro.2018.12.009

Lichtenstein GR Loftus EV Isaacs KL Regueiro MD Gerson LB Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481-517. doi:10.1038/ajg.2018.27

Nguyen GC Loftus EV Jr Hirano I , et al. American Gastroenterological Association Institute guideline on the management of Crohn’s disease after surgical resection. Gastroenterology. 2017;152:271-275. doi:10.1053/j.gastro.2016.10.038

Terdiman JP Gruss CB Heidelbaugh JJ , et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1459-1463. doi:10.1053/j.gastro.2013.10.047

National Institute for Health and Care Excellence. Ulcerative colitis: management. Clinical guideline: CG166. Published June 26, 2013. Accessed April 3, 2019. https://www.nice.org.uk/guidance/cg166/resources/ulcerative-colitis-management-pdf-35109695126725

National Institute for Health and Care Excellence. Crohn’s disease: management. Clinical guideline: CG152. Published October 10, 2012. Accessed April 3, 2019. https://www.nice.org.uk/guidance/cg152/resources/crohns-disease-management-pdf-35109627942085

Turner D Ruemmele FM Orlanski-Meyer E , et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis—an evidence-based consensus guideline from the European Crohn’s and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:292-310. doi:10.1097/MPG.0000000000002036

Turner D Ruemmele FM Orlanski-Meyer E , et al. Management of paediatric ulcerative colitis, part 1: ambulatory care—an evidence-based guideline from European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:257-291. doi:10.1097/MPG.0000000000002035

Kavia RB De Ridder D Constantinescu CS Stott CG Fowler CJ. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. 2010;16:1349-1359. doi:10.1177/1352458510378020

Freeman RM Adekanmi O Waterfield MR Waterfield AE Wright D Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006;17:636-641. doi:10.1007/s00192-006-0086-x

Brady CM DasGupta R Dalton C Wiseman OJ Berkley KJ Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler. 2004;10:425-433. doi:10.1191/1352458504ms1063oa

Langford RM Mares J Novotna A , et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260:984-997. doi:10.1007/s00415-012-6739-4

Svendsen KB Jensen TS Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253. doi:10.1136/bmj.38149.566979.AE

Rog DJ Nurmikko TJ Friede T Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812-819. doi:10.1212/01.wnl.0000176753.45410.8b

Flachenecker P Henze T Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice—results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol. 2014;71:271-279. doi:10.1159/000357427

Flachenecker P Henze T Zettl UK. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol. 2014;72:95-102. doi:10.1159/000360285

Zajicek JP Hobart JC Slade A Barnes D Mattison PG ; MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83:1125-1132. doi:10.1136/jnnp-2012-302468

Corey-Bloom J Wolfson T Gamst A , et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012;184:1143-1150. doi:10.1503/cmaj.110837

Collin C Davies P Mutiboko IK Ratcliffe S ; Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14:290-296. doi:10.1111/j.1468-1331.2006.01639.x

Novotna A Mares J Ratcliffe S , et al; Sativex Spasticity Study Group. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18:1122-1131. doi:10.1111/j.1468-1331.2010.03328.x

Collin C Ehler E Waberzinek G , et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32:451-459. doi:10.1179/016164109X12590518685660

Zajicek J Fox P Sanders H , et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362:1517-1526. doi:10.1016/S0140-6736(03)14738-1

Zajicek JP Sanders HP Wright DE , et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76:1664-1669. doi:10.1136/jnnp.2005.070136

Vaney C Heinzel-Gutenbrunner M Jobin P , et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10:417-424. doi:10.1191/1352458504ms1048oa

Wade DT Robson P House H Makela P Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17:21-29. doi:10.1191/0269215503cr581oa

Wade DT Makela P Robson P House H Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434-441. doi:10.1191/1352458504ms1082oa

Shen Q Lu H Xie D , et al. Association between suicide and multiple sclerosis: an updated meta-analysis. Mult Scler Relat Disord. 2019;34:83-90. doi:10.1016/j.msard.2019.06.012.

Wade DT Collin C Stott C Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler. 2010;16:707-714. doi:10.1177/1352458510367462

Association of British Neurologists. ABN statement on the use of marijuana (cannabis) related products in the treatment of complex epilepsies. Published December 2018. Updated March 2019. Accessed April 8, 2019. https://cdn.ymaws.com/www.theabn.org/resource/collection/0F3D17B6-B02E-4B65-B0EA-4AF6F605EF42/ABN_2019_Statement_on_use_of_marijuana__cannab.pdf

National Institute for Health and Care Excellence. Cannabis-based products for medicinal use. NICE guideline: NG144. Published November 11, 2019. Accessed December 2019. https://www.nice.org.uk/guidance/indevelopment/gid-ng10124

National Multiple Sclerosis. Medical marijuana (cannabis) FAQs. Accessed April 8, 2019. https://www.nationalmssociety.org/Treating-MS/Complementary-Alternative-Medicines/Marijuana

Söderpalm AH Schuster A de Wit H. Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac. Pharmacol Biochem Behav. 2001;69:343-350. doi:10.1016/s0091-3057(01)00533-0

Rocha FCM Stéfano SC De Cássia Haiek R Oliveira LMR Da Silveira DX . Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl). 2008;17:431-443. doi:10.1111/j.1365-2354.2008.00917.x

Chang AE Shiling DJ Stillman RC , et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer. 1981;47:1746-1751. doi:10.1002/1097-0142(19810401)47:7<1746::aid-cncr2820470704>3.0.co;2-4

Chang AE Shiling DJ Stillman RC , et al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate: a prospective, randomized evaluation. Ann Intern Med. 1979;91:819-824. doi:10.7326/0003-4819-91-6-819

Duran M Pérez E Abanades S , et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. 2010;70:656-663. doi:10.1111/j.1365-2125.2010.03743.x

Ungerleider JT Andrysiak T Fairbanks L Goodnight J Sarna G Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer. 1982;50:636-645. doi:10.1002/1097-0142(19820815)50:4<636::aid-cncr2820500404>3.0.co;2-4

Orr LE McKernan JF Bloome B. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med. 1980;140:1431-1433. doi:10.1001/archinte.140.11.1431

Frytak S Moertel CG O’Fallon JR , et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy: a comparison with prochlorperazine and a placebo. Ann Intern Med. 1979;91:825-830. doi:10.7326/0003-4819-91-6-825

Sallan SE Zinberg NE Frei E III . Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med. 1975;293:795-797. doi:10.1056/NEJM197510162931603

Meiri E Jhangiani H Vredenburgh JJ , et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23:533-543. doi:10.1185/030079907x167525

McCabe M Smith FP Macdonald JS Woolley PV Goldberg D Schein PS. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs. 1988;6:243-246. doi:10.1007/bf00175407

Lane M Vogel CL Ferguson J , et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage. 1991;6:352-359. doi:10.1016/0885-3924(91)90026-z

Chan HS Correia JA MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics. 1987;79:946-952.

Dalzell AM Bartlett H Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child. 1986;61:502-505. doi:10.1136/adc.61.5.502

Niederle N Schütte J Schmidt CG. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr. 1986;64:362-365. doi:10.1007/bf01728184

Pomeroy M Fennelly JJ Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol. 1986;17:285-288. doi:10.1007/bf00256701

Niiranen A Mattson K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol. 1985;8:336-340. doi:10.1097/00000421-198508000-00013

Ahmedzai S Carlyle DL Calder IT Moran F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer. 1983;48:657-663. doi:10.1038/bjc.1983.247

Johansson R Kilkku P Groenroos M. A double-blind, controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev. 1982;9(suppl B):25-33. doi:10.1016/s0305-7372(82)80032-7

Jones SE Durant JR Greco FA Robertone A. A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev. 1982;9(suppl B):45-48. doi:10.1016/s0305-7372(82)80035-2

Levitt M. Nabilone vs placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat Rev. 1982;9(suppl B):49-53. doi:10.1016/s0305-7372(82)80036-4

Einhorn L. Nabilone: an effective antiemetic agent in patients receiving cancer chemotherapy. Cancer Treat Rev. 1982;9(suppl B):55-61. doi:10.1016/s0305-7372(82)80037-6

Wada JK Bogdon DL Gunnell JC Hum GJ Gota CH Rieth TE . Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev. 1982;9(suppl B):39-44. doi:10.1016/s0305-7372(82)80034-0

Steele N Gralla RJ Braun DW Jr Young CW. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep. 1980;64:219-224.

Herman TS Einhorn LH Jones SE , et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 1979;300:1295-1297. doi:10.1056/NEJM197906073002302

Tafelski S Häuser W Schäfer M. Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews. Schmerz. 2016;30:14-24. doi:10.1007/s00482-015-0092-3

Smith LA Azariah F Lavender VT Stoner NS Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015;(11):CD009464. doi:10.1002/14651858.CD009464.pub2

Hesketh PJ Kris MG Basch E , et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2017;35:3240-3261. doi:10.1200/JCO.2017.74.4789

Ettinger DS Berger MJ Aston J , et al. NCCN guidelines version 1.2019: antiemesis. Accessed May 19, 2019. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf

Lynch ME Ware MA. Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol. 2015;10:293-301. doi:10.1007/s11481-015-9600-6

Lynch ME Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72:735-744. doi:10.1111/j.1365-2125.2011.03970.x

Mücke M Phillips T Radbruch L Petzke F Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;(3):CD012182. doi:10.1002/14651858.CD012182.pub2

Issa MA Narang S Jamison RN , et al. The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. Clin J Pain. 2014;30:472-478. doi:10.1097/AJP.0000000000000022

Ware MA Wang T Shapiro S Collet JP ; COMPASS Study Team. Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). J Pain. 2015;16:1233-1242. doi:10.1016/j.jpain.2015.07.014

Wilsey B Marcotte T Tsodikov A , et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9:506-521. doi:10.1016/j.jpain.2007.12.010

Wilsey B Marcotte T Deutsch R Gouaux B Sakai S Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14:136-148. doi:10.1016/j.jpain.2012.10.009

Wilsey B Marcotte TD Deutsch R Zhao H Prasad H Phan A. An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease. J Pain. 2016;17:982-1000. doi:10.1016/j.jpain.2016.05.010

Serpell M Ratcliffe S Hovorka J , et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014;18:999-1012. doi:10.1002/j.1532-2149.2013.00445.x

Nurmikko TJ Serpell MG Hoggart B Toomey PJ Morlion BJ Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133:210-220. doi:10.1016/j.pain.2007.08.028

Skrabek RQ Galimova L Ethans K Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9:164-173. doi:10.1016/j.jpain.2007.09.002

Blake DR Robson P Ho M Jubb RW McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45:50-52. doi:10.1093/rheumatology/kei183

Wallace MS Marcotte TD Umlauf A Gouaux B Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain. 2015;16:616-627. doi:10.1016/j.jpain.2015.03.008

EUCTR2006-001598-10-GB. A double blind, randomised, placebo controlled, parallel group study of Sativex® in the treatment of subjects with pain due to diabetic neuropathy—GWDN0603 Study of Sativex in subjects with peripheral diabetic neuropathy. Accessed April 14, 2019. https://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006-001598-10-GB.

Hoggart B Ratcliffe S Ehler E , et al. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. J Neurol. 2015;262:27-40. doi:10.1007/s00415-014-7502-9

Narang S Gibson D Wasan AD , et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008;9:254-264. doi:10.1016/j.jpain.2007.10.018

Haroutounian S Ratz Y Ginosar Y , et al. The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study. Clin J Pain. 2016;32:1036-1043. doi:10.1097/AJP.0000000000000364

Savage SR Romero-Sandoval A Schatman M , et al. Cannabis in pain treatment: clinical and research considerations. J Pain. 2016;17:654-668. doi:10.1016/j.jpain.2016.02.007

International Association for the Study of Pain. IASP Presidential Task Force on Cannabis and Cannabinoid Analgesia. Accessed April 14, 2019. https://www.iasp-pain.org/About/Content.aspx?ItemNumber=7917

Häuser W Finn DP Kalso E , et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22:1547-1564. doi:10.1002/ejp.1297

Elms L Shannon S Hughes S Lewis N. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. J Altern Complement Med. 2019;25:392-397. doi:10.1089/acm.2018.0437

Browne KC Dolan M Simpson TL Fortney JC Lehavot K. Regular past year cannabis use in women veterans and associations with sexual trauma. Addict Behav. 2018;84:144-150. doi:10.1016/j.addbeh.2018.04.007

Dworkin ER Kaysen D Bedard-Gilligan M Rhew IC Lee CM. Daily-level associations between PTSD and cannabis use among young sexual minority women. Addict Behav. 2017;74:118-121. doi:10.1016/j.addbeh.2017.06.007

Loflin M Earleywine M Bonn-Miller M. Medicinal versus recreational cannabis use: patterns of cannabis use, alcohol use, and cued-arousal among veterans who screen positive for PTSD. Addict Behav. 2017;68:18-23. doi:10.1016/j.addbeh.2017.01.008

Shannon S Opila-Lehman J. Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm J. 2016;20:16-005. doi:10.7812/TPP/16-005

Greer GR Grob CS Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoactive Drugs. 2014;46:73-77. doi:10.1080/02791072.2013.873843

Roitman P Mechoulam R Cooper-Kazaz R Shalev A. Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig. 2014;34:587-591. doi:10.1007/s40261-014-0212-3

Mashiah M. Medical cannabis as treatment for chronic combat PTSD: promising results in an open label pilot study. Paper presented at: Patients Out of Time Conference; April 28, 2012; Tucson, Arizona.

Bonn-Miller MO Babson KA Vandrey R. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014;136:162-165. doi:10.1016/j.drugalcdep.2013.12.008

Passie T Emrich HM Karst M Brandt SD Halpern JH. Mitigation of post-traumatic stress symptoms by cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal. 2012;4:649-659. doi:10.1002/dta.1377

Villagonzalo KA Dodd S Ng F Mihaly S Langbein A Berk M. The relationship between substance use and posttraumatic stress disorder in a methadone maintenance treatment program. Compr Psychiatry. 2011;52:562-566. doi:10.1016/j.comppsych.2010.10.001

Ruglass LM Shevorykin A Radoncic V , et al. Impact of cannabis use on treatment outcomes among adults receiving cognitive-behavioral treatment for PTSD and substance use disorders. J Clin Med. 2017;6:14. doi:10.3390/jcm6020014

Gentes EL Schry AR Hicks TA , et al. Prevalence and correlates of cannabis use in an outpatient VA posttraumatic stress disorder clinic. Psychol Addict Behav. 2016;30:415-421. doi:10.1037/adb0000154

Johnson MJ Pierce JD Mavandadi S , et al. Mental health symptom severity in cannabis using and non-using veterans with probable PTSD. J Affect Disord. 2016;190:439-442. doi:10.1016/j.jad.2015.10.048

Wilkinson ST Stefanovics E Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76:1174-1180. doi:10.4088/JCP.14m09475

Bedard-Gilligan M Garcia N Zoellner LA Feeny NC. Alcohol, cannabis, and other drug use: engagement and outcome in PTSD treatment. Psychol Addict Behav. 2018;32:277-288. doi:10.1037/adb0000355

El-Solh AA. Management of nightmares in patients with posttraumatic stress disorder: current perspectives. Nat Sci Sleep. 2018;10:409-420. doi:10.2147/NSS.S166089

Jetly R Heber A Fraser G Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585-588. doi:10.1016/j.psyneuen.2014.11.002

Cameron C Watson D Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014;34:559-564. doi:10.1097/JCP.0000000000000180

Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009;15:84-88. doi:10.1111/j.1755-5949.2008.00071.x

Mizrachi Zer-Aviv T Segev A Akirav I . Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention. Behav Pharmacol. 2016;27:561-569. doi:10.1097/FBP.0000000000000253

The Management of Posttraumatic Stress Disorder Work Group. VA/DOD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder, Version 3.0. Published June 2017. Accessed May 9, 2019. https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf

American Psychological Association. Clinical practice guideline for the treatment of posttraumatic stress disorder (PTSD) in adults. Adopted February 24, 2017. Accessed May 9, 2019. https://www.apa.org/ptsd-guideline/ptsd.pdf

Phoenix Australia Centre for Posttraumatic Mental Health. Australian guidelines for the treatment of acute stress disorder and posttraumatic stress disorder. Published 2013. Accessed May 9, 2019. https://www.phoenixaustralia.org/wp-content/uploads/2015/03/Phoenix-ASD-PTSD-Guidelines.pdf

National Institute for Health and Care Excellence. Posttraumatic stress disorder. NICE guideline: NG116. Published December 5, 2018. Accessed May 9, 2019. https://www.nice.org.uk/guidance/ng116

Council on Addiction Psychiatry. Resource document on APA opposition to the use of cannabis for PTSD. Published February 2019. Accessed May 9, 2019. https://www.psychiatry.org/File%20Library/Psychiatrists/Directories/Library-and-Archive/resource_documents/Resource-Document-2019-APA-Opposition-to-the-Use-of-Cannabis-for-PTSD.pdf

Van Lancker A Velghe A Van Hecke A , et al. Prevalence of symptoms in older cancer patients receiving palliative care: a systematic review and meta-analysis. J Pain Symptom Manage. 2014;47:90-104. doi:10.1016/j.jpainsymman.2013.02.016

Portenoy RK Thaler HT Kornblith AB , et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res. 1994;3:183-189. doi:10.1007/bf00435383

Donovan KA Chang YD Oberoi-Jassal R , et al. Relationship of cannabis use to patient-reported symptoms in cancer patients seeking supportive/palliative care. J Palliat Med. 2019;22:1191-1195. doi:10.1089/jpm.2018.0533

Carter GT Flanagan AM Earleywine M Abrams DI Aggarwal SK Grinspoon L. Cannabis in palliative medicine: improving care and reducing opioid-related morbidity. Am J Hosp Palliat Care. 2011;28:297-303. doi:10.1177/1049909111402318

Chan A Molloy L Pertile J Ilesias M . A review for Australian nurses: cannabis use for anti-emesis among terminally ill patients in Australia. Aust J Adv Nurs. 2017;24:43-47.

Costello J. Preserving the independence of people living with multiple sclerosis towards the end of life. Int J Palliat Nurs. 2017;23:474-483. doi:10.12968/ijpn.2017.23.10.474

Cyr C Arboleda MF Aggarwal SK , et al. Cannabis in palliative care: current challenges and practical recommendations. Ann Palliat Med. 2018;7:463-477. Published correction appears in Ann Palliat Med. 2019;8:215-217. doi:10.21037/apm.2018.06.04

Dzierżanowski T. Prospects for the use of cannabinoids in oncology and palliative care practice: a review of the evidence. Cancers (Basel). 2019;11:E129. doi:10.3390/cancers11020129

Häuser W Fitzcharles MA Radbruch L Petzke F. Cannabinoids in pain management and palliative medicine. Dtsch Arztebl Int. 2017;114:627-634. doi:10.3238/arztebl.2017.0627

Peat S. Using cannabinoids in pain and palliative care. Int J Palliat Nurs. 2010;16:481-485. doi:10.12968/ijpn.2010.16.10.79211

Spencer N Shaw E Slaven M. Medical cannabis use in an outpatient palliative care clinic: a retrospective chart review. J Pain Manage. 2016;9:507-513.

Kuhlen M Hoell JI Gagnon G , et al. Effective treatment of spasticity using dronabinol in pediatric palliative care. Eur J Paediatr Neurol. 2016;20:898-903. doi:10.1016/j.ejpn.2016.07.021

Sawhney M Fletcher GG Rice J Watt-Watson J Rawn T . Guidelines on management of pain in cancer and/or palliative care. Published September 22, 2017. Accessed April 26, 2019. https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/full/pebc18-4f_0.pdf

Allan GM Ramji J Perry D , et al. Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Physician. 2018;64:111-120.

Kosel BW Aweeka FT Benowitz NL , et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS. 2002;16:543-550.